Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression

L Dubois; T Dresselaers; W Landuyt; K Paesmans; A Mengesha; B G Wouters; P Van Hecke; J Theys; P Lambin

doi:10.1038/sj.bjc.6603624

Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression

Br J Cancer. 2007 Mar 12;96(5):758-61. doi: 10.1038/sj.bjc.6603624. Epub 2007 Feb 20.

Authors

L Dubois¹, T Dresselaers, W Landuyt, K Paesmans, A Mengesha, B G Wouters, P Van Hecke, J Theys, P Lambin

Affiliation

¹ Department of Radiation Oncology (Maastro Lab), GROW Research Institute, University of Maastricht, UNS 50/23, 6200 MD, Maastricht, The Netherlands.

Abstract

The potential utility of tumour-selective 5-fluorouracil treatment using attenuated Salmonella serovar typhimurium recombinant for cytosine deaminase (TAPET-CD) has been documented in experimental settings. The present data demonstrate that in vivo (19)F-magnetic resonance spectroscopy measurements allow the outcome prediction of this prokaryotic-based therapy, demonstrating the necessity of non-invasive real-time imaging techniques for treatment monitoring.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / analysis
Antineoplastic Agents / metabolism*
Antineoplastic Agents / therapeutic use
Blotting, Western
Chromatography, Thin Layer
Cytosine Deaminase / genetics
Cytosine Deaminase / therapeutic use*
Female
Flucytosine / analysis
Flucytosine / metabolism*
Flucytosine / therapeutic use
Fluorouracil / analysis
Fluorouracil / metabolism*
Fluorouracil / therapeutic use
Genetic Therapy / methods*
Genetic Vectors
Humans
Magnetic Resonance Spectroscopy
Mice
Neoplasms, Experimental / therapy*
Prodrugs / analysis
Prodrugs / metabolism
Prodrugs / therapeutic use
Salmonella typhimurium / genetics
Xenograft Model Antitumor Assays

Substances

Antineoplastic Agents
Prodrugs
Flucytosine
Cytosine Deaminase
Fluorouracil